FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to recombinant antibodies binding CD96 (differentiation cluster 96), and can be used in medicine for treating cancer.
EFFECT: disclosed CD96-binding protein, which is a human IgG1 antibody to CD96 with improved characteristics, is able to stimulate anti-tumour efficacy mediated by NK-cells.
9 cl, 28 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
